A Liposomal Nanoparticle Platform Technology For The Delivery Oftaxanes - A Case Study | 24682
Journal of Material Sciences & Engineering
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
The development of novel therapeutic candidates as well as some approved compounds faces the critical challenge of limited
aqueous solubility, which results in reduced efficacy. Formulation strategies employed to deliver such compounds typically rely
on the use of less desirable excipients such as ethanol, DMSO, cremophore, detergents etc. While these excipients improve solubility,
they are toxic, often precipitates upon dilution in vivo or in vitro reducing the bioavailability. In many cases their use may result in
undesirable side effects or sensitivities which reduce the therapeutic window and often require specific pre-treatment with other
drugs. These formulations also require complicated steps and therefore more expensive manufacturing processes. Currently many
liposomal and polymers nanoparticles are under investigation for drug deliver to overcome and solve the limitations of conventional
drug delivery systems such as nonspecific bio-distribution, lack of aqueous solubility, poor oral bioavailability, and low therapeutic
indices. The particle size and surface characteristics have been optimized to increase their circulation time in the bloodstream
and to improve the safety, pharmacokinetics, and bio-distribution of drugs. Scientists at CuriRx, Inc. have developed a novel,
liposomal nanoparticle platform technology for the delivery of such therapeutic compounds with not only better safety, efficacy,
pharmacokinetics/pharmacodynamics profiles but also with easy scalable manufacturing process. A case study of development efforts
of docetaxel encapsulated in the liposomal nanoparticle having significant clinical and manufacturing advantages over Taxotere:
increased efficacy, improved pharmacokinetics, reduced toxicity, excellent stability, and enhanced solubility, will be presented.
Charan R Behl, PhD, is a consultant to CuriRx, Inc. and he is also engaged in the development of drug products including oral controlled release, transdermal,
dermatological, parenteral, nasal, and ophthalmic drug products. He previously held executive positions at Elite Pharma, Northvale, NJ, and Nastec h Pharma,
Hauppauge, NY; and senior positions at Roche, NJ. He got his PhD in Pharmaceutical Sciences from the University of Michigan, Ann Arbor, MI; MS in Pharmaceutical
Chemistry from Duquesne University, Pittsburg, PA; and BPharm (Hons) from BITS, Pilani, India. He has, over the past 30+ years worked in the research and
development of ?challenging drugs?. He has over 200 research articles, book chapters, and abstracts at major conferences; over 40 patents granted, under review,
and in-preparation. He has co-organized many symposia working closely with colleagues from the academia, industry, the NIH, and the FDA. He is also a Fellow
of the American Association of Pharmaceuticals Scientists (AAPS).
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals